Introduction
Angiogenesis takes place during development and fetal implantation, and is also observed in several diseases (for a review see Ferrara, 1999) . Vascular endothelial growth factor (VEGF) is an essential angiogenic signal because of its chemotactic and proliferative effects on vascular endothelial cells. VEGF also has nonangiogenic roles such as chemoattracting macrophages (Clauss et al., 1990; Barleon et al., 1996) and enhancing neuronal survival (Sondell et al., 1999; Jin et al., 2000) . Several VEGF isoforms are generated by the alternative splicing of the 8-exon VEGF mRNA (Tischer et al., 1991) .
Extensive research has been devoted to investigating the transcriptional, post-transcriptional and translational mechanisms regulating VEGF expression. VEGF expression is induced by hypoxia (Forsythe et al., 1996) , as well as by several growth factors and cytokines, including PDGF (Finkenzeller et al., 1997) , tumor necrosis factor-a (Ryuto et al., 1996) and interleukin1b (IL-1b) (Tanaka et al., 2000) . Prostaglandins also induce VEGF (Sko¨ld et al., 2000) . The VEGF promoter contains numerous transcription factor-binding sites, mostly clustered in two regions. The proximal cluster includes Sp1 and AP-2 sites, and mediates VEGF transcription by cytokines and growth factors (Ryuto et al., 1996; Finkenzeller et al., 1997; Tanaka et al., 2000) . The distal cluster, located approximately 1 kb from the transcriptional start site, includes the hypoxia response element, AP-1 and STAT-3-binding sites and mediates VEGF induction by insulin, hypoxia and acidosis (Forsythe et al., 1996; Treins et al., 2002; Xu et al., 2002) .
VEGF is expressed by various cell types during development, cancer, arteriosclerosis, inflammation and injury (Ferrara, 1999) . Oncostatin-M (OSM), a cytokine of the IL-6 family, is also expressed in some of these conditions (Modur et al., 1997; Mukouyama et al., 1998; Ruprecht et al., 2001; Hao et al., 2002) . OSM is produced mainly by activated macrophages and microglia (Radka et al., 1993; Repovic and Benveniste, 2002) . OSM receptors contain the gp130 subunit, which is shared with other members of the IL-6 family, including leukemia inhibitory factor (LIF), IL-6, IL-11, ciliary neurotrophic factor, cardiotrophin-1 and cardiotrophin-1-like cytokine (Murphy et al., 1997) . A functional OSM receptor, in addition to gp130, contains either the OSM receptor b (OSMRb) or LIF receptor b (LIFRb) subunit (Mosley et al., 1996) . The OSMRb/gp130 heterodimer is specific for OSM, whereas the LIFRb/gp130 receptor is shared between OSM and LIF. Binding of OSM to either the LIFRb/gp130 or OSMRb/gp130 receptor results in the activation of the signal transducer and activator of transcription (STAT) pathway (Schaefer et al., 2000) . Within the central nervous system, OSM has been localized in inflammatory plaques of multiple sclerosis patients (Ruprecht et al., 2001) . In vitro evidence indicates that OSM modulates inflammatory events in the brain by upregulating IL-6, cyclooxygenase-2 (COX-2) and a1-antichymotrypsin expression in astrocytes and astroglioma cells (Kordula et al., 1998; Van Wagoner et al., 2000; Repovic et al., 2003) . Furthermore, OSM has been found to have angiogenic properties, as ectopic application of OSM to rabbit cornea induces in vivo angiogenesis comparable to that induced by bFGF (Vasse et al., 1999) .
We have recently reported OSM production by microglia, the resident macrophages of the brain (Repovic and Benveniste, 2002) . Subsequently, we demonstrated that OSM upregulates COX-2 expression in astrocytes and astroglioma cell lines (Repovic et al., 2003) . Given the angiogenic effects of OSM (Vasse et al., 1999) and the established role of COX-2 in angiogenesis (Shono et al., 2001) , we hypothesized that OSM may induce other angiogenic factors such as VEGF. Here, we report that OSM treatment of human astroglioma cell lines results in the upregulation of VEGF expression. OSM induces VEGF expression via the OSMRb/gp130 receptor, in a STAT-3-dependent manner. The OSM effect on VEGF expression is further enhanced by IL1b. This novel mechanism of VEGF induction in astroglioma cells may offer a link between previous reports of elevated OSM and VEGF expression in gliomas (Pietsch et al., 1997; Chaudhry et al., 2001; Lilja et al., 2001; Hao et al., 2002) , and suggest novel therapeutic targets in glioma treatment.
Results

OSM and IL-1b induce VEGF expression in astroglioma cells
Treatment of the human astroglioma cell line CRT-MG with OSM, IL-1b or both cytokines for 3-48 h results in a time-dependent increase in VEGF protein (Figure 1a) . After 48 h, IL-1b induces a modest 1.7-fold increase in VEGF levels over the baseline, whereas OSM treatment results in Bthreefold higher VEGF levels as compared to untreated control. OSM and IL-1b together induce a Bsevenfold increase in VEGF protein levels after 48 h (Figure 1a) .
Ribonuclease protection assay (RPA) was used to monitor VEGF mRNA levels upon treatment with OSM, IL-1b or both cytokines for 6-48 h. OSM induced VEGF mRNA Btwofold over baseline levels by 6 h, and this level of induction persisted until 48 h ( Figures  1b and c) . Interestingly, IL-1b treatment did not induce VEGF mRNA expression. However, IL-1b and OSM together increased VEGF mRNA levels Bsevenfold after 36 h of treatment (Figures 1b and c ). These data demonstrate that OSM and IL-1b cooperatively induce VEGF at the mRNA and protein level in a timedependent manner. In addition to VEGF, OSM and IL1b modestly induce the expression of VEGF-C mRNA Figure 1 Time course of VEGF protein and mRNA induction by OSM and IL-1b. CRT-MG human astroglioma cells were treated for 3-48 h with OSM (10 ng/ml), IL-1b (1 ng/ml), or both cytokines. VEGF levels in the supernatants were determined using ELISA and normalized to total cellular protein. The mean7s.d. of three experiments are shown (a). CRT-MG astroglioma cells were stimulated with OSM (10 ng/ml), IL-1b (1 ng/ml) or both cytokines for 6-48 h. At indicated times, total RNA was isolated and analyzed for the presence of VEGF and GAPDH mRNA using RPA (b). For each condition, the intensity of the VEGF band was normalized to the respective GAPDH value. Fold induction, calculated as the ratio of normalized VEGF values between a cytokine-treated sample and the untreated control, is shown in (c).
Results shown are representative of two experiments
Induction of VEGF by Oncostatin-M P Repovic et al (Figure 1b ), a gene related to VEGF (Jeltsch et al., 1997) .
To determine the optimal dose of OSM and IL-1b required for VEGF induction, CRT-MG astroglioma cells were treated with increasing doses of IL-1b in the absence or presence of 10 ng/ml of OSM (Figure 2a ). IL1b at 0.1-1 ng/ml synergized with OSM for optimal VEGF induction. Alternatively, the treatment consisted of escalating doses of OSM without or with 1 ng/ml of IL-1b (Figure 2b ). In this case, OSM at 10-30 ng/ml induced optimal expression. We used 10 ng/ml of OSM and 1 ng/ml of IL-1b in subsequent experiments.
OSM and IL-1b induce VEGF expression in multiple astroglioma cell lines
In response to OSM and IL-1b stimulation, human astroglioma cell lines CH235-MG, CRT-MG, U373-MG and U87-MG all showed increased expression of VEGF protein ( Figure 3 ) and mRNA (data not shown). OSM induced a two-to threefold increase in VEGF protein levels (Figure 3 ). IL-1b alone did not significantly increase VEGF levels; however, the combination of IL-1b and OSM induced VEGF protein expression in all the cell lines tested, resulting in VEGF concentrations from 3.6-fold (CH235-MG) to sevenfold (U373-MG) higher than untreated controls (Figure 3 ).
Prostaglandins are not required for the induction of VEGF expression by OSM or OSM plus IL-1b Sko¨ld et al. (2000) reported that injection of prostaglandins into rat spinal cord increased VEGF expression by astrocytes. We have shown that OSM and IL-1b synergistically induce prostaglandin (PGE 2 ) production by astroglioma cells (Repovic et al., 2003) . We therefore tested whether OSM and IL-1b, by inducing PGE 2 , initiate an autocrine mechanism whereby VEGF is induced. Indomethacin, an inhibitor of prostaglandin synthesis, failed to alter VEGF protein levels induced by OSM and/or IL-1b treatment ( Figure 4a ). Accordingly, indomethacin did not attenuate the induction of VEGF mRNA by OSM and IL-1b ( Figure 4b ). Similar results were obtained using two other prostaglandin synthesis inhibitors, ibuprofen and acetylsalicylic acid (data not shown). These results demonstrate that prostaglandins are not required for VEGF induction by OSM and IL1b in astroglioma cells. /well) were plated in six-well plates and treated for 24 h with OSM alone (0.1-30 ng/ml) or in combination with IL-1b (1 ng/ml). VEGF levels were determined using ELISA. The mean7s.d. of three experiments are shown (b) Figure 3 Human astroglioma cell lines express VEGF upon treatment with OSM and IL-1b. Human astroglioma cell lines CH235-MG, CRT-MG, U373-MG and U87-MG were plated in 100 mm dishes to 70% confluency and stimulated for 24 h with OSM (10 ng/ml), IL-1b (1 ng/ml) or both cytokines. Supernatants were analyzed for VEGF protein concentration using ELISA. Results shown are representative of two experiments Induction of VEGF by Oncostatin-M P Repovic et al
OSM induces VEGF promoter activity in a STAT-3-dependent manner
To understand the molecular basis by which OSM and IL-1b induce VEGF expression, we studied the effect of OSM and IL-1b on VEGF promoter activity, using a construct containing the (À2274, þ 50) fragment of the human VEGF promoter (Tai et al., 2002) . U87-MG cells transiently transfected with this construct showed Btwofold increase in luciferase activity upon treatment with OSM ( Figure 5a ). This level of promoter activity is in agreement with the observed effect of OSM on VEGF mRNA and protein in this cell line (Figure 3) . Interestingly, IL-1b alone had no effect on VEGF promoter activity, and the combination of OSM and IL1b did not further enhance VEGF promoter activity (data not shown).
Using serial 5 0 deletions of the (À2274, þ 50) construct, we identified a region between À1171 and À786 bp of the human VEGF promoter that is required for OSM inducibility (Figure 5a ). This region contains sites for Sp1, HIF-1a, STAT-3 and AP-2 (Figure 5a ) (Tischer et al., 1991; Forsythe et al., 1996; Niu et al., 2002) . We tested whether STAT-3 is required for OSM induction of VEGF promoter activity using a STAT-3 DN mutant that has a phenylalanine substitution at Tyr705 (STAT-3F) (Nakajima et al., 1996) . Tyr705 is phosphorylated by JAKs, and is essential for STAT-3 dimerization. Consequently, STAT-3F cannot be phosphorylated, and outcompetes endogenous STAT-3 for binding to gp130/OSMRb, thus preventing STAT-3 activation. U373-MG cells stably transfected with the STAT-3 DN construct, as well as U373-MG cells stably transfected with control vector pcDNA3, were transiently transfected with the (À1171, þ 50) VEGF promoter construct. After 24 h in the presence of OSM, VEGF promoter activity was increased by Btwofold in pcDNA3-transfected cells (Figure 5b ). However, in STAT-3 DN-expressing cells, VEGF promoter activity was not enhanced upon OSM treatment ( Figure 5b) .
We also examined endogenous VEGF mRNA and protein levels upon OSM treatment of cells expressing the STAT-3 DN construct. Whereas control cells transfected with pcDNA3 upregulated VEGF mRNA B2.2-fold upon OSM treatment, STAT-3 DN-expressing cells showed only a 1.2-fold induction (Figure 5c ). Similarly, OSM-induced VEGF protein expression was abolished in STAT-3 DN-expressing cells (Figure 5d ). These results indicate that OSM induction of VEGF in astroglioma cells is mediated by STAT-3.
OSMRb/gp130 receptor mediates OSM induction of VEGF expression OSM signals through two receptors; heterodimers of gp130 and OSMRb or gp130 and LIFRb (Taga, 1997) . To determine which of these receptors is utilized by OSM, we used neutralizing antibodies to all three receptor subunits (gp130, LIFRb and OSMRb) and evaluated their effect on OSM induction of VEGF. The neutralizing antibody to gp130, in a dose-dependent manner, inhibited VEGF production induced by OSM (Figure 6 ). The neutralizing antibody against OSMRb also significantly reduced VEGF induction by OSM (Figure 6 ). In contrast, the neutralizing antibody to LIFRb had no effect. These data indicate that OSM utilizes the heterodimer of OSMRb and gp130 to induce VEGF expression. /100 mm dish) were pretreated with indomethacin (10 mm) for 1 h before stimulation with OSM (10 ng/ml), IL-1b (1 ng/ml) or both cytokines for 24 h. Total RNA was extracted and analyzed for the presence of VEGF and GAPDH mRNA using RPA (b, lower panel). Quantification and fold inductions were calculated as described in the legend of Figure 1 In vivo expression of OSM in human glioblastoma multiforme tumor biopsies
We investigated whether OSM is expressed in biopsies of glioblastoma multiforme (GBM), a particularly malignant form of brain cancer known to overexpress VEGF (Pietsch et al., 1997; Chaudhry et al., 2001; Yao et al., 2001) . OSM protein expression was analysed by Western blot in human brain biopsy samples from GBM patients, non-neoplastic brain controls and normal autopsy brain. OSM was detected in all nine GBM samples (Figures 7a and c) , but was not detected in the five non-neoplastic brain samples (Figure 7a ). Low levels of OSM were detected in four of five normal autopsy brain samples (Figure 7c ). These results Figure 5 OSM enhances VEGF gene transcription in a STAT-3-dependent manner. Deletion constructs of the human VEGF promoter (1.8 mg) plus control p-CMV-b-gal vector (0.2 mg) were transiently cotransfected into U87-MG cells, as described in Materials and methods. Transfected cells were treated in the absence or presence of OSM (10 ng/ml) for 24 h, then luciferase activity was measured and normalized to the activity of b-galactosidase for each sample. Fold induction is calculated as the ratio of normalized luciferase activity in OSM-treated samples versus untreated samples, with the fold induction of pGL2-transfected samples set at 1.00. Results shown are mean7s.d. of three independent experiments. Transcription factor-binding sites in the (À1171, À786) region of the human VEGF promoter are also shown (a). U373-MG cells stably expressing dominant-negative STAT-3, as well as pcDNA3-transfected cells, were transiently cotransfected with the (À1171, þ 50) VEGF construct and pCMV-b-gal, and treated with OSM (10 ng/ml). After 24 h, luciferase activity was measured and normalized to b-galactosidase activity to yield relative luciferase units (RLUs). The mean7s.d. of three experiments (b) are shown. U373-MG cells stably transfected with STAT-3 DN or pcDNA3 were stimulated with OSM (10 ng/ml) for 24 h. Total RNA was isolated and analyzed for VEGF and GAPDH mRNA using RPA. Fold inductions were determined as described in the legend of Figure 1 . Results are representative of three experiments (c). VEGF levels were determined using ELISA. The mean7s.d. of three experiments are shown (d) b Figure 6 OSM induction of VEGF expression is mediated by the OSMRb/gp130 receptor. CRT-MG cells were pretreated with neutralizing anti-gp130 antibody (0.01-10 mg/ml), anti-OSMRb antibody (0.01-10 mg/ml), anti-LIFRb antibody (0.01-10 mg/ml) or appropriate isotype control antibodies for 1 h before treatment with OSM (10 ng/ml) for 24 h. VEGF levels were determined using ELISA. The mean7s.
d. of three experiments are shown
Induction of VEGF by Oncostatin-M P Repovic et al collectively indicate that GBM samples contain higher levels of OSM protein, as compared to the normal brain.
Discussion
OSM has been reported to promote angiogenesis (Vasse et al., 1999) , and we recently found that it increases COX-2 expression in astroglioma cells (Repovic et al., 2003) . Thus, we hypothesized that other angiogenic factors, in addition to COX-2, may be induced by OSM treatment. We found that in four human astroglioma cell lines, OSM induced VEGF expression (Figures 1  and 3 ). The increase was further amplified in the presence of IL-1b, another cytokine commonly elevated in astrogliomas (Figures 1 and 3 ) (Nagashima et al., 2002) . VEGF production is characteristic of solid tumors, such as gliomas, breast and prostate cancers. Up to 95% of astrogliomas produce VEGF (Pietsch et al., 1997) , and there is a direct correlation between astroglioma grade and the level of VEGF production (Chaudhry et al., 2001; Yao et al., 2001) . Astroglioma specimens also express increased OSM mRNA levels (Lilja et al., 2001; Hao et al., 2002) , although the cell(s) of origin was not determined. Here, we show that GBM tumor biopsies also express elevated OSM protein levels ( Figure 7 ). Our data suggest that OSM may be a novel regulator of VEGF expression in astroglioma. We did not identify the cellular source(s) of OSM in the GBM samples, but suspect it is likely tumor-infiltrating microglia/macrophages, rather than the tumor cells themselves. We have previously shown that in vitro, astroglioma cells do not produce OSM in response to a variety of stimuli (Repovic and Benveniste, 2002) .
Prostaglandins have been shown to induce VEGF expression (Sko¨ld et al., 2000) . In our system, however, prostaglandins are not responsible for VEGF induction by OSM and IL-1b, since inhibitors of prostaglandin production (e.g. indomethacin) had no effect on VEGF expression (Figure 4) . These results argue, instead, for a more direct effect of OSM and IL-1b on VEGF expression.
Using neutralizing antibodies against gp130, OSMRb and LIFRb, we demonstrated that OSMRb and gp130 subunits, but not the LIFRb subunit, are required for VEGF induction by OSM (Figure 6 ). Therefore, OSM induction of VEGF expression in astrogliomas is a unique property of OSM, not shared with other IL-6 family members. Accordingly, we have not observed VEGF production by astrogliomas treated with LIF or other IL-6 family cytokines (data not shown), although IL-6 has been reported to upregulate VEGF expression in other cell types (Cohen et al., 1996) .
We next investigated the effect of OSM on VEGF promoter activity, and identified a (À1171, À786) region of the VEGF promoter that is required for inducibility by OSM (Figure 5a ). This region contains binding sites for several transcription factors, including STAT-3. STAT-3 is indeed required for this response, since the expression of a STAT-3 DN mutant blocks OSM induction of VEGF promoter activity (Figure 5b) , as well as OSM induction of endogenous VEGF mRNA and protein (Figures 5c and d) . This effect of STAT-3 DN is not due to decreased expression of OSM receptors, because the expression of OSMRb and gp130 is not altered on astroglioma cells stably transfected with STAT-3 DN (data not shown). STAT-3 has recently been reported to promote VEGF expression in several tumors (Niu et al., 2002) . In that study, the factor(s) responsible for STAT-3 activation was not identified. Our findings of OSM expression in GBM biopsies (Figure 7) suggest that OSM contributes to STAT-3 activation and VEGF expression in brain cancer.
In conclusion, the data presented here outline a novel mechanism for regulating VEGF expression in astroglioma cells by OSM and IL-1b. These two cytokines, commonly elevated in cancer, may thus promote angiogenesis via the induction of VEGF. Future work will be directed at investigating the mechanism underlying the IL-1b contribution to this process, as well as assessing the significance and applicability of this proposed role for OSM in vivo.
Materials and methods
Reagents
Recombinant human OSM and IL-1b, and the immunoassay kits for human VEGF were obtained from R&D Systems (Minneapolis, MN, USA). Neutralizing antibodies to LIFRb and gp130 were also obtained from R&D Systems, while antiOSMRb neutralizing antibody was a gift from the Immunex Corporation (Seattle, WA, USA). Indomethacin was purchased from Biomol (Plymouth Meeting, PA, USA). Antisense 
Cell lines
The human astroglioma cell line CRT-MG was grown in RPMI 1640 medium supplemented with 10% heat-inactivated fetal bovine serum (HI-FBS), 2 mm l-glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin, as previously described (Ma et al., 2001) . CH235-MG and U87-MG human astroglioma cells were grown in DMEM/Ham's F-12 medium supplemented as above, with 10 mm HEPES (Ma et al., 2001) . U373-MG human astroglioma cells were grown in Dulbecco's minimum essential medium (DMEM) supplemented as above, including 0.1 mm nonessential amino-acid mixture and 1 mm sodium pyruvate, as previously described (Van Wagoner et al., 2000) .
Plasmids
The KpnI to NheI genomic fragment of the human VEGF promoter cloned in the pGL2 basic vector (Promega, Madison, WI, USA) was a kind gift from Dr Kenneth C Anderson and Dr Yu-Tzu Tai (Dana Farber Cancer Institute, Boston, MA, USA) (Tai et al., 2002) . This construct, spanning the (À2274, þ 50) region of the VEGF promoter (Tischer et al., 1991) , was digested with SacI/NcoI or PstI/NcoI and religated to obtain (À1171, þ 50) and (À786, þ 50) truncations.
The dominant-negative STAT-3 construct (STAT-3 DN) pCAGGS-neo-STAT-3F was a kind gift from Dr M Hibi, Dr T Hirano and Dr K Nakajima (Osaka University Medical School, Osaka, Japan) (Nakajima et al., 1996) . U373-MG astroglioma cells were transfected with the STAT-3 DN or pcDNA3 control vector and selected using G418 sulfate (1 mg/ ml) to obtain stable transfectants. Cells were propagated in the above media for U373-MG cells supplemented with G418 sulfate (1 mg/ml).
Transient transfections and analysis
Transfections were carried out using the Fugene 6 reagent (Roche Applied Science, Indianapolis, IN, USA) according to the manufacturer's directions, using a 3 : 1 ratio of Fugene 6 to DNA. Briefly, astroglioma cells (2 Â 10 5 /well) plated 12-18 h before transfection were cotransfected with 1.8 mg of the VEGF promoter construct or pGL2 basic vector plus 0.2 mg of pCMV-b-galactosidase vector as a control for transfection efficiency. After 12 h of recovery, cells were stimulated with OSM (10 ng/ml) for 24 h, lysed and assayed in triplicate for luciferase activity, as previously described (Nguyen and Benveniste, 2000) . Extracts were also assayed in triplicate for b-galactosidase activity to yield relative luciferase activity. Fold induction was calculated as the ratio of relative luciferase activity between OSM and medium-treated samples that were transfected with the same construct.
VEGF protein measurement
Cells were plated at either 2 Â 10 5 cells/well in six-well plates, or 2-3 Â 10 6 cells/100 mm dish (Costar, Cambridge, MA, USA), in serum-containing media overnight to adhere. Before stimulation, cells were washed once with PBS, fresh media was added, along with the cytokines, as indicated, for 0-48 h. Supernatants were then harvested and centrifuged at 1000 g for 5 min to remove cells. VEGF concentrations were measured using a human VEGF ELISA kit, according to the manufacturer's instructions. Cells were lysed in 1% SDS and the total cellular protein was measured using the BCA Protein Assay (Pierce, Rockford, IL, USA). All VEGF concentrations were normalized to total protein, and are expressed as picograms of VEGF per micrograms of total protein.
RNA isolation, riboprobes and RPA
Cells were plated at 2-3 Â 10 6 cells per 100 mm dish. Upon confluence, the cells were washed with PBS, the medium was replaced and cells were stimulated with cytokines for the indicated times. The total cellular RNA was isolated using TRIZOL (Invitrogen, Carlsbad, CA, USA), as previously described (Van Wagoner et al., 2000) .
The human angiogenesis multiprobe template set (hANG-IO-1) was used to generate a 177 bp VEGF and a 124 bp GAPDH riboprobe by in vitro transcription. In vitro transcription of riboprobes was performed with the T7 in vitro transcription kit (Ambion, Austin, TX, USA), as previously described (Van Wagoner et al., 2000) .
RPA was carried out according to the manufacturer's instructions. Briefly, 20 mg of total RNA was hybridized with appropriate riboprobes containing 3 Â 10 5 cpm/probe/sample at 561C overnight as previously described (Van Wagoner et al., 2000) . Quantification of the protected RNA fragments was performed by scanning with the PhosphorImager (Molecular Dynamics, Sunnyvale, CA, USA). Values for VEGF mRNA were normalized to respective GAPDH mRNA levels for each experimental condition.
Western blotting
Non-neoplastic brain biopsy, normal autopsy brain and glioblastoma tumor biopsy samples were lysed using a Polytron in 1% RIPA lysis buffer containing protease inhibitors (100 mm phenylmethylsulfonyl fluoride, 10 mg/ml aprotinin, 10 mg/ml leupeptin and 100 mm sodium vanadate), followed by centrifugation (35 000 rpm, 1 h, 41C) and determination of the protein concentration in the supernatant. Samples (30 mg) were electrophoresed on a 12% disulfidereduced SDS-PAGE gel, transferred onto Immobilon-P membrane, blocked and reacted with 1 mg/ml of anti-OSM rabbit IgG (Santa Cruz Biotechnology, Santa Cruz, CA, USA) overnight at 41C. The blots were washed in 0.2% Tween 20 in TBS, and incubated with 0.025 mg/ml horseradish-peroxidaseconjugated anti-rabbit IgG (Bio-Rad Laboratories, Hercules, CA, USA) for 1 h at 221C. The blots were developed using the enhanced chemiluminescence kit (Amersham Biosciences, Piscataway, NJ, USA). The blots were stripped and reblotted with 1 mg/ml of anti-tubulin mouse monoclonal antibody (Upstate Biotech, Charlottesville, VA, USA) overnight at 41C, as previously described (Hecker et al., 2002) . Tissues were received from the UAB Brain Tumor Bank of the Cooperative Tissue Network, in accordance with the University of Alabama at Birmingham Human Tissue committee policies, Institutional Review Board exemption #X98049003. The five non-neoplastic brain biopsy samples were obtained from patients with a seizure disorder and the tissue was diagnosed as mesial sclerosis. The nine tumor biopsies were diagnosed as glioblastomas (WHO Grade IV tumors).
Abbreviations VEGF, vascular endothelial growth factor; OSM, oncostatin-M; HIF, hypoxia-inducible factor; IL-1b, interleukin-1b; MAPK, mitogen-activated protein kinase; STAT, signal transducer and activator of transcription; COX, cyclooxygenase; LIF, leukemia inhibitory factor; PGE, prostaglandin E; DN, dominant negative.
